new_0222_0359|PRLD|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0359|PRLD|Long Name|1|1|Prelude Therapeutics Inc Total Current Assets (Quarterly) (USD)|Prelude Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Prelude Therapeutics Inc Inventories (Quarterly) (USD)|Prelude Therapeutics Inc Net PP&E (Quarterly) (USD)|Prelude Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Prelude Therapeutics Inc Total Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Deposits (Quarterly) (USD)|Prelude Therapeutics Inc Book Value (Quarterly) (USD)|Prelude Therapeutics Inc Retained Earnings (Quarterly) (USD)|Prelude Therapeutics Inc Treasury Stock (Quarterly) (USD)|Prelude Therapeutics Inc EV to Revenues|Prelude Therapeutics Inc EV to Earnings|Prelude Therapeutics Inc EV to Free Cash Flow|Prelude Therapeutics Inc EV to Assets (Quarterly)|Prelude Therapeutics Inc PS Ratio|Prelude Therapeutics Inc PE Ratio|Prelude Therapeutics Inc Price to Book Value|Prelude Therapeutics Inc PEG Ratio|Prelude Therapeutics Inc Debt to Equity Ratio|Prelude Therapeutics Inc Dividend Yield|Prelude Therapeutics Inc Shareholder Yield (TTM)|Prelude Therapeutics Inc Percent of Shares Outstanding Short|Prelude Therapeutics Inc Total Receivables (Quarterly) (USD)|Prelude Therapeutics Inc Total Payables (Quarterly) (USD)|Prelude Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Return on Invested Capital|Prelude Therapeutics Inc Quality Ratio Score|Prelude Therapeutics Inc Momentum Score|Prelude Therapeutics Inc Beta (1Y)|Prelude Therapeutics Inc Sustainable Growth Rate (TTM)|Prelude Therapeutics Inc Institutional Investor Ownership Percentage|Prelude Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Prelude Therapeutics Inc Total Employees (Annual)|Prelude Therapeutics Inc EPS Diluted (Quarterly) (USD)|Prelude Therapeutics Inc Shares Outstanding|Prelude Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Ordinary Shares Number (Quarterly)|Prelude Therapeutics Inc Payout Ratio|Prelude Therapeutics Inc Quick Ratio (Quarterly)|Prelude Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Prelude Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Prelude Therapeutics Inc Effective Tax Rate (TTM)|Prelude Therapeutics Inc Return on Equity|Prelude Therapeutics Inc Net Income (TTM) (USD)|Prelude Therapeutics Inc Revenue (TTM) (USD)|Prelude Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Prelude Therapeutics Inc Revenue (Quarterly) (USD)|Prelude Therapeutics Inc Gross Profit (Quarterly) (USD)|Prelude Therapeutics Inc SG&A Expense (Quarterly) (USD)|Prelude Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Interest Income (Quarterly) (USD)|Prelude Therapeutics Inc Price (USD)|Prelude Therapeutics Inc Total Return Price (USD)|Prelude Therapeutics Inc Enterprise Value (USD)|Prelude Therapeutics Inc 30-Day Average Daily Volume|Prelude Therapeutics Inc 1 Year Price Returns (Daily)
new_0222_0359|PRLD|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0359|PRLD||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily
new_0222_0359|PRLD||5|5|104.428571429|104.428571429|0|104.428571429|0|104.428571429|104.428571429|104.428571429|0|104.428571429|104.428571429|0|0|0|1.44918032787|0|0|0|1.44715447154|0|0|1.44892473118|0|15.1764705882|0|104.428571429|104.428571429|0|0|30|30.2|0|0|91.4444444444|91.4|91.4444444444|27.1764705882|0|104.428571429|0|0|91.4444444444|91.4285714286|0|0|91.5|0|0|0|0|91.4444444444|91.4444444444|91.4444444444|0|1.44892473118|1.44892473118|1.44892473118|1.45189504373|1.43333333333
new_0222_0359|PRLD||6|6|7|7|0|7|0|7|7|7|0|7|7|0|0|0|305|0|0|0|369|0|0|372|0|34|0|7|7|0|0|4|5|0|0|9|5|9|17|0|7|0|0|9|7|0|0|6|0|0|0|0|9|9|9|0|372|372|372|343|120
new_0222_0359|PRLD||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0359|PRLD|201909|201909|201909||||||||||||||||||||||||||||||||||32.4018||-0.2078||||||-0.2078|||||||||1.394|-6.734|-6.734||||||
new_0222_0359|PRLD|201912|201912|201912|20.224|18.879||1.647||71.283|4.835|66.448||-49.412|-50.497|||||||||||||||1.974|0|||||||32.4018||-0.3098|||42.4546|||-0.3098|||||||||1.246|-10.039|-10.039||||||
new_0222_0359|PRLD|202003|202003|202003||||||||||||||||||||||||||||||||||32.4018||-0.2935||||||-0.2935|0||||||||1.201|-9.511|-9.511||||||
new_0222_0359|PRLD|202006|202006|202006|30.697|29.716||1.575||102.058|5.639|96.419||-69.311|-71.416|||||||||||||||3.471|0|||||||42.4546|51|-0.2687|||42.4546|||-0.2687|0|||-37.692|||||1.66|-11.408|-11.408||||||
new_0222_0359|PRLD|202009|202009|202009|238.061|234.792||1.62||11.374|11.359|0.015||228.307|-88.176||||||||5.7676|||0||0.0132||5.074|0.004|||||||3.1945|55|-5.25|43.7034||43.7034|||-5.25|-167.929|||-47.718|||||2.851|-16.76|-16.76||30.13|30.13|1081.9914||
new_0222_0359|PRLD|202010|202009|202009|||||||||||||||||||6.7439|||0||0.7318|||||||||||||||||||||||||||||||35.23|35.23|1304.8788||
new_0222_0359|PRLD|202011|202009|202009|||||||||||||||||||9.8526|||0||1.212|||||||||||||43.7034||||||||||||||||||51.47|51.47|2014.622|117394.5333|
new_0222_0359|PRLD|202012|202012|202012|220.809|218.309||2.48||11.407|11.375|0.032||212.183|-107.426||||-62.1572||||14.738|||0||2.8086||3.92|0.004|||||||43.7057|68|-0.4404|43.7057||43.7057|||-0.4404|1.299|||-56.929|||||4.874|-19.25|-19.25||71.55|71.55|2908.8338|195008.9667|
new_0222_0359|PRLD|202101|202012|202012|||||||||||||||-59.9803||||14.2578|||0||3.1494|||||||||||||46.5784||||||||||||||||||64.95|64.95|2806.9581|317060.4|
new_0222_0359|PRLD|202102|202012|202012|||||||||||||||-57.3726||||13.6827|||0||3.0515|||||||||||||||||||||||||||||||62.33|62.33|2684.9227|160864.1333|
new_0222_0359|PRLD|202103|202103|202103|365.018|362.99||4.813||13.264|12.424|0.84||356.567|-128.726||||-30.8656||||5.686|||0||3.6742||4.842|0.005|||||||45.122|105|-0.47|46.7909||46.7909|||-0.47|-161.424|||-68.718|||||5.497|-21.3|-21.3||43.33|43.33|1664.4597|200349.4333|
new_0222_0359|PRLD|202104|202103|202103|||||||||||||||-29.3071||||5.4503|||0||4.1279|||||||||||||46.8968||||||||||||||||||41.44|41.44|1580.4134|285619.6667|
new_0222_0359|PRLD|202105|202103|202103|||||||||||||||-23.5374||||4.5777|||0||4.3691|||||||||||||46.9582||||||||||||||||||34.76|34.76|1269.277|214130.8667|
new_0222_0359|PRLD|202106|202106|202106|344.575|343.119||5.006||15.22|14.677|0.543||334.361|-155.591||||-15.3749||||4.0277|||0||7.231||6.844|0.005|||||||46.0571|100|-0.58|47.0387||47.0387|||-0.58|0|||-84.175|||||5.513|-26.865|-26.865||28.63|28.63|1003.599|224939.7|
new_0222_0359|PRLD|202107|202106|202106|||||||||||||||-17.8323||||4.5075|||0||8.7773|||||||||||||||||||||||||||||||32.04|32.04|1164.0009|216628.9667|
new_0222_0359|PRLD|202108|202106|202106|||||||||||||||-20.4925||||5.0268|||0||8.7618|||||||||||||47.0935||||||||||||||||||35.69|35.69|1337.648|178832.8667|
new_0222_0359|PRLD|202109|202109|202109|325.897|320.865||5.32||19.975|19.663|0.312||311.242|-186.278||||-15.3787||||4.7383|||0||9.4094||11.062|0.005||||2.5212|||46.3308|113|-0.66|47.1918||47.1918|||-0.66|0|||-98.102|||||8.115|-30.687|-30.687||31.25|31.25|1153.8788|354084.1|3.7172
new_0222_0359|PRLD|202110|202109|202109|||||||||||||||-6.7808||||2.6656|||0||10.587||||||4|2.0799||||||||||||||||||||||||17.58|17.58|508.7668|745763.1667|-49.4537
new_0222_0359|PRLD|202111|202109|202109|||||||||||||||-4.716||||2.1678|||0||11.4933||||||1|-0.3083||||||47.2154||||||||||||||||||14.29|14.29|353.8431|334619.8|-72.2363
new_0222_0359|PRLD|202112|202112|202112|295.115|291.233||5.636||19.201|19.201|0||285.897|-219.12||||-3.5108||||2.0729|||0||10.8962||7.84|0.005|||1|-1.1063|||46.6759||-0.71|47.6023||47.6023|||-0.71|0|||-111.694|||||7.832|-32.842|-32.842||12.45|12.45|301.4156|468497.9333|-82.5996
new_0222_0359|PRLD|202201|202112|202112|||||||||||||||-2.1136||||1.6534|||0||9.4872||||||1|-0.3823||||||||||||||||||||||||9.93|9.93|181.4578|449422.9333|-84.7113
new_0222_0359|PRLD|202202|202112|202112|||||||||||||||-1.5037||||1.4702|||0||9.0653||||||1|-0.4638||||||||||||||||||||||||8.83|8.83|129.0953|263318.1333|-85.8335
new_0222_0359|PRLD|202203|202203|202203|||||||||||||||-1.2819||||1.4036|||0|||||||||||||||||||||||||||||||||8.43|8.43|110.0544|220043.8667|-83.9764